Recursion Pharmaceuticals (RXRX) to Release Quarterly Earnings on Tuesday

Key Points

• Recursion Pharmaceuticals is set to announce its Q2 2025 earnings on August 5th, with analysts predicting a loss of ($0.34) per share and revenue of $15.38 million.
• In its last earnings report, the company missed expectations, reporting a loss of ($0.50) EPS and $14.75 million in revenue, compared to estimates of ($0.44) EPS and $18.12 million.
• Recursion Pharmaceuticals' stock has seen a 2.4% increase, trading at $5.95, with a current market capitalization of $2.42 billion.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Tuesday, August 5th. Analysts expect Recursion Pharmaceuticals to post earnings of ($0.34) per share and revenue of $15.38 million for the quarter.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The firm had revenue of $14.75 million during the quarter, compared to analysts' expectations of $18.12 million. During the same period in the previous year, the company posted ($0.39) earnings per share. The company's quarterly revenue was up 7.2% compared to the same quarter last year. On average, analysts expect Recursion Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Recursion Pharmaceuticals Price Performance

Shares of Recursion Pharmaceuticals stock traded up $0.01 on Monday, reaching $5.69. The stock had a trading volume of 3,822,773 shares, compared to its average volume of 25,243,387. Recursion Pharmaceuticals has a 1 year low of $3.79 and a 1 year high of $12.36. The company has a market cap of $2.31 billion, a P/E ratio of -3.23 and a beta of 0.93. The company has a current ratio of 4.11, a quick ratio of 4.11 and a debt-to-equity ratio of 0.02. The business's 50 day moving average is $5.28 and its two-hundred day moving average is $5.93.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Brighton Jones LLC boosted its holdings in Recursion Pharmaceuticals by 49.4% in the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company's stock worth $137,000 after acquiring an additional 6,699 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Recursion Pharmaceuticals by 7.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company's stock worth $953,000 after purchasing an additional 12,372 shares during the last quarter. Focus Partners Wealth purchased a new position in shares of Recursion Pharmaceuticals in the first quarter worth about $77,000. AQR Capital Management LLC purchased a new position in shares of Recursion Pharmaceuticals in the first quarter worth about $890,000. Finally, Royal Bank of Canada raised its stake in shares of Recursion Pharmaceuticals by 627.6% in the first quarter. Royal Bank of Canada now owns 269,013 shares of the company's stock worth $1,423,000 after purchasing an additional 232,038 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.

Analyst Ratings Changes

RXRX has been the topic of a number of recent research reports. Morgan Stanley initiated coverage on Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 price objective on the stock. Needham & Company LLC reissued a "buy" rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, July 8th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and a consensus target price of $7.00.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.